Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) rose 8.1% during mid-day trading on Thursday . The company traded as high as $7.40 and last traded at $7.31. Approximately 6,584,147 shares changed hands during trading, a decline of 5% from the average daily volume of 6,933,797 shares. The stock had previously closed at $6.76.
Analyst Ratings Changes
Separately, Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $9.25.
Get Our Latest Analysis on RXRX
Recursion Pharmaceuticals Stock Performance
The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock's 50-day moving average price is $6.82 and its 200-day moving average price is $7.09. The company has a market capitalization of $2.07 billion, a P/E ratio of -4.71 and a beta of 0.85.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). The company had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company's revenue for the quarter was up 147.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.43) EPS. As a group, equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.
Insider Activity at Recursion Pharmaceuticals
In other news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $6.32, for a total value of $94,800.00. Following the transaction, the chief financial officer now directly owns 1,426,506 shares of the company's stock, valued at $9,015,517.92. This trade represents a 1.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Tina Marriott sold 6,000 shares of the stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $6.31, for a total value of $37,860.00. Following the completion of the sale, the chief operating officer now owns 521,138 shares of the company's stock, valued at $3,288,380.78. The trade was a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 70,341 shares of company stock worth $488,290 over the last ninety days. 15.75% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Recursion Pharmaceuticals
A number of institutional investors have recently bought and sold shares of the business. Axxcess Wealth Management LLC increased its position in Recursion Pharmaceuticals by 4.3% in the 3rd quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company's stock worth $289,000 after purchasing an additional 1,795 shares during the last quarter. Green Alpha Advisors LLC lifted its stake in Recursion Pharmaceuticals by 2.9% in the third quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company's stock valued at $427,000 after acquiring an additional 1,800 shares during the last quarter. Amalgamated Bank lifted its stake in shares of Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company's stock valued at $54,000 after purchasing an additional 2,459 shares during the last quarter. Victory Capital Management Inc. increased its position in Recursion Pharmaceuticals by 13.5% during the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company's stock worth $164,000 after buying an additional 2,598 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Recursion Pharmaceuticals by 5.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 52,530 shares of the company's stock valued at $346,000 after acquiring an additional 2,667 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Further Reading
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.